

CHECKUP BELOWBELOW 40FEMALE SSION NO : 0290WJ005049 AGE/SEX : 34 Years Female NT ID : MRSKF050389290 DRAWN : RECEIVED : 28/10/2023 11:17:58 REPORTED : 30/10/2023 16:37:00 REPORTED : 30/10/2023 16:37:00 sults Biological Reference Interval Units DFEMALE
DFEMALE
S RHYTHM.
RWISE NORMAL ECG.
SIGNIFICANT
D :- LSCS 2022. SIGNIFICANT
IER :- DM.
SIGNIFICANT
SIGNIFICANT
mts
Kgs
BMI & Weight Status as follows/sqmts
Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
1AL
1AL
RWEIGHT
AGE
1AL
ENLARGED OR TENDER

Dr.Arpita Pasari, MD Consultant Pathologist





 \mathbf{D}_{i}

59.

5

E

- 3

Ż

3

Ì

3



PATIENT NAME : MRS. KUMARI PUNAM (BOB	E49236) REF. /	DOCTOR : DR. MEDI WHEEL FULL BODY HEALTH	
CODE/NAME & ADDRESS : C000138355		CHECKUP BELOWBELOW 40FEMALE	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0290WJ00		
F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : MRSKF0503		
DELHI	CHIENT BATTENT ID: (BOBE4923	REPORTED : 30/10/2023 11:17:58 REPORTED : 30/10/2023 16:37:00	
NEW DELHI 110030 8800465156			
~~~~~			
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
CAROTID PULSATION	NORMAL		
TEMPERATURE	AFEBRILE		
PULSE	71/MIN, REGULAR, ALL PER BRUIT	RIPHERAL PULSES WELL FELT, NO CAROTID	
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	118/78 MM HG (SUPINE)	mm/Hg	
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	NORMAL		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			
SPINE	NORMAL		
F			



Dr.Arpita Pasari, MD Consultant Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel: 0731 2490008

Page 2 Of 21

t







PATIENT NAME : MRS. KUMARI PUNAM (BOBE4	9236) REF.		OR. MEDI WHEEL FULL B CHECKUP BELOWBELOW	
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290WJ00	)5049	AGE/SEX : 34 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSKF0503	389290	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CHIENT PATIENT ID: (BOBE492	36)	RECEIVED : 28/10/202	23 11:17:58
NEW DELHI 110030			REPORTED : 30/10/202	23 16:37:00
8800465156				
Test Report Status <u>Final</u>	Results	Biological	Reference Interval	Units
JOINTS	NORMAL			
BASIC EYE EXAMINATION				
CONJUNCTIVA	NORMAL			
EYELIDS	NORMAL			
EYE MOVEMENTS	NORMAL			
CORNEA	NORMAL			
DISTANT VISION RIGHT EYE WITHOUT GLASSES	6/6, WITHIN NORMAL LIMI	т		
DISTANT VISION LEFT EYE WITHOUT GLASSES	6/6, WITHIN NORMAL LIMI	Т		
NEAR VISION RIGHT EYE WITHOUT GLASSES	N6, WITHIN NORMAL LIMIT	Г		
NEAR VISION LEFT EYE WITHOUT GLASSES	N6, WITHIN NORMAL LIMIT	Г		
COLOUR VISION	NORMAL			
BASIC ENT EXAMINATION				
EXTERNAL EAR CANAL	NORMAL			
TYMPANIC MEMBRANE	NORMAL			
NOSE	NO ABNORMALITY DETECT	ED		
SINUSES	NORMAL			
THROAT	NORMAL			
TONSILS	NOT ENLARGED			
BASIC DENTAL EXAMINATION				
TEETH	NORMAL			
GUMS	HEALTHY			
SUMMARY				
RELEVANT HISTORY	NOT SIGNIFICANT			
RELEVANT GP EXAMINATION FINDINGS	OVERWEIGHT			
REMARKS / RECOMMENDATIONS	NONE			
FITNESS STATUS				
FITNESS STATUS	FIT (WITH MEDICAL ADVIC	E) (AS PER F	REQUESTED PANEL OF	TESTS)

Pepita

Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 3 Of 21

View Report







PATIENT NAME : MRS. KUMARI PUNAM (BOBE	49236) REF	F. DOCTOR : DR. MEDI WHEEL FULL BODY HEA CHECKUP BELOWBELOW 40FEMA	
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290WJC</b> PATIENT ID : MRSKF05( SHIAN BATIENT ID: (BOBE49	0389290 DRAWN :	7:58
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	

### Comments

(X-RAY REDUSED BY CANDIDATE DUE TO PREGNANCY)

CLINICAL FINDINGS :-

RAISED URIC ACID.

OVER WEIGHT STATUS.

FITNESS STATUS :-

FITNESS STATUS : FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

ADVICE : WEIGHT REDUCTION, LOW FAT& CARBOHYDRATE DIET AND REGULAR PHYSICAL EXERCISE FOR OVERWEIGHT STATUS

NEED PHYSICIAN CONSULTATION FOR LIFE STYLE MODIFICATION.

Dr.Arpita Pasari, MD **Consultant Pathologist** 





Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49		R. MEDI WHEEL FULL BODY HEALTH HECKUP BELOWBELOW 40FEMALE
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSKF050389290 GEIENTBATIENT ID: (BOBE49236)	AGE/SEX : 34 Years Female DRAWN : RECEIVED : 28/10/2023 11:17:58 REPORTED : 30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results	Units

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

## ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN NO ABNORMALITIES DETECTED

TMT OR ECHO

## **CLINICAL PROFILE**

### Comments

ECHO DONE

**IMPRESSION** :-

- Normal 2D Echo Study - LVEF 70%

### Interpretation(s) MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for . These are then further correlated with details of the job under consideration to eventually fit the right man to the right job. Basis the above, Agilus diagnostic classifies a candidate's Fitness Status into one of the following categories:

• Fit (As per requested panel of tests) - AGILUS Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.

Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician'''

Physician """"'s consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job. • Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.

• Unfit (As per requested panel of tests) - An unfit report by Agilus diagnostic Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.



Dr.Arpita Pasari, MD **Consultant Pathologist** 

Page 5 Of 21

Vie<u>w Report</u>



/iew Details



**Test Report Status** 

**Final** 



**Biological Reference Interval** Units

PATIENT NAME : MRS. KUMARI PUNAM (BOBE4	9236) REF. DOCTOR :	DR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290WJ005049</b> РАПЕНТ ID : MRSKF050389290 СЫТЕЛТВАПЕНТ ID: (BOBE49236)	AGE/SEX :34 Years Female DRAWN : RECEIVED :28/10/2023 11:17:58 REPORTED :30/10/2023 16:37:00

Results

Н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.6	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT	4.36	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	5.97	4.0 - 10.0	thou/µL
PLATELET COUNT	173	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	36.4	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)	83.6	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.8	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	34.5	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.4 High	11.6 - 14.0	%
MENTZER INDEX	19.2		
MEAN PLATELET VOLUME (MPV)	13.2 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	60	40 - 80	%
LYMPHOCYTES	35	20 - 40	%
MONOCYTES	03	2 - 10	%
EOSINOPHILS	02	1 - 6	%
BASOPHILS	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	3.58	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.09	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.18 Low	0.20 - 1.00	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.12	0.02 - 0.50	thou/µL

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive



Dr.Arpita Pasari, MD **Consultant Pathologist** 



Patient Ref. No. 775000005251157





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49		R. MEDI WHEEL FULL BODY HEALTH HECKUP BELOWBELOW 40FEMALE
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSKF050389290	AGE/SEX : 34 Years Female DRAWN : RECEIVED : 28/10/2023 11:17:58 REPORTED : 30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.



Dr.Arpita Pasari, MD Consultant Pathologist



Page 7 Of 21

View Report







PATIENT NAME : MRS. KUMARI PUNAM (BOBE49			HEEL FULL BOD	
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290WJ005049	AGE/SEX	: 34 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : MRSKF050389290	DRAWN	:	
DELHI	GLIENT PATIENT ID: (BOBE49236)	RECEIVED	: 28/10/2023	11:17:58
NEW DELHI 110030		REPORTED	:30/10/2023	16:37:00
8800465156				

Test	Report	Status	Final
------	--------	--------	-------

Results

Biological Reference Interval Units

,					
	HAEMATOLOGY				
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE					
ERYTHROCYTE SEDIMENTATION RATE (ESR), BLOOD	WHOLE				
E.S.R METHOD : MODIFIED WESTERGREN	42 High	0 - 20	mm at 1 hr		
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	WHOLE				
HBA1C	5.3	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%		
METHOD : HPLC TECHNOLOGY		-			
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL		

### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Dr.Arpita Pasari, MD **Consultant Pathologist** 

Page 8 Of 21

Vie<u>w Report</u>



Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE4		PR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE
F-703 LADO SARAT MEHRALILISOUTH WEST	ABHA NU : C	AGE/SEX :34 Years Female DRAWN : RECEIVED :28/10/2023 11:17:58 REPORTED :30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

### HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr.Arpita Pasari, MD **Consultant Pathologist** 



Page 9 Of 21

View Report

Vie<u>w</u> Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE4	P236) REF. DOCTOR	DR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE
E-703 LADO SARAT MEHRALILISOUTH WEST	ACCESSION NO : <b>0290WJ005049</b> PATIENT ID : MRSKF050389290 GLIENT BATIENT ID: (BOBE49236)	AGE/SEX :34 Years Female DRAWN : RECEIVED :28/10/2023 11:17:58 REPORTED :30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units

	IMMUNOHAEMATOLOGY	
MEDI WHEEL FULL BODY HEALTH C	IECKUP BELOW 40FEMALE	
ABO GROUP & RH TYPE, EDTA WHO	E BLOOD	
ABO GROUP METHOD : TUBE AGGLUTINATION	TYPE O	
RH TYPE METHOD : TUBE AGGLUTINATION	POSITIVE	

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Bepita

Dr.Arpita Pasari, MD **Consultant Pathologist** 



Page 10 Of 21

View Report View Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49		HEEL FULL BOD	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0290WJ005049</b> РАПЕНТ ID : MRSKF050389290 GEIENT BATIENT ID: (BOBE49236)	:34 Years : :28/10/2023 :30/10/2023	

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

**Biological Reference Interval** Units

<u></u>	BIOCHEMISTRY		]
MEDI WHEEL FULL BODY HEALTH CHECKUP BEI	OW 40FEMALE		,
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	98	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	102	Normal: < 140, Impaired Glucose Tolerance:140-199 Diabetic > or = 200	mg/dL
METHOD : HEXOKINASE LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	132	Desirable: <200 BorderlineHigh : 200-239 High : > or = 240	mg/dL
METHOD : OXIDASE, ESTERASE, PEROXIDASE		5	
TRIGLYCERIDES	121	Desirable: $< 150$ Borderline High: 150 - 199 High: 200 - 499 Very High : $>$ or $= 500$	mg/dL
METHOD : ENZYMATIC ASSAY		,	
HDL CHOLESTEROL	27 Low	< 40 Low > or = 60 High	mg/dL
METHOD : DIRECT- NON IMMUNOLOGICAL			
CHOLESTEROL LDL	81	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :
NON HDL CHOLESTEROL METHOD : CALCULATED	105	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL

Bepita

Dr.Arpita Pasari, MD Consultant Pathologist

Page 11 Of 21





Interpretation(s)



PATIENT NAME : MRS. KUMARI PUNAM (BOBE4	9236) REF	. <b>DOCTOR :</b> DR CH		HEEL FULL BOI LOWBELOW 4	
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290WJO</b> РАПЕНТ ID : MRSKF050 АНЕЛТВАПЕНТ ID: (BOBE49	389290 I 236) I	DRAWN RECEIVED	:34 Years : :28/10/2023 :30/10/2023	
Test Report Status <u>Final</u>	Results	Biological R	Reference	e Interval	Units
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED	24.2	< or = 30		mg	g/dL
CHOL/HDL RATIO	4.9 High	3.3 - 4.4			
LDL/HDL RATIO	3	0.5 - 3.0 D 3.1 - 6.0 B Risk			

>6.0 High Risk

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Category			
Extreme risk group	A.CAD with $> 1$ feature of high risk group		
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 Familial Homozygous Hypercholesterolem	major risk factors or evidence of end organ damage 3.	
High Risk	<ol> <li>Three major ASCVD risk factors.</li> <li>Diabetes with 1 major risk factor or no evidence of end organ damage.</li> <li>CKD stage 3B or 4.</li> <li>LDL &gt;190 mg/dl</li> <li>Extreme of a single risk factor.</li> <li>Coronary Artery Calcium - CAC &gt;300 AU.</li> <li>Lipoprotein a &gt;/= 50mg/dl</li> <li>Non stenotic carotid plaque</li> </ol>		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk F	actors	
1. Age > or = 45 year	rs in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use	
2. Family history of p	premature ASCVD	4. High blood pressure	
5. Low HDL			
ewer treatment goal	s and statin initiation thresholds based on t	the risk categories proposed by LAI in 2020	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals	Goals Consider Drug Therapy		Therapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60)<="" =="" td=""><td>&gt;OR = 50</td><td>&gt;OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

Dr.Arpita Pasari, MD Consultant Pathologist



Page 12 Of 21





PATIENT NAME : MRS. KUMARI PUNAM (BOBE	19236) REF		I WHEEL FULL BODY HEALTH P BELOWBELOW 40FEMALE
CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0290WJ(</b> РАПЕНТ ID : MRSKF05 АНЕМТВАПЕНТ ID: (BOBE49	0389290 DRAWN 9236) RECEIV	EX :34 Years Female I : ED :28/10/2023 11:17:58 ED :30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results	Biological Refere	nce Interval Units
BILIRUBIN, TOTAL METHOD : JENDRASSIK AND GROFF	0.84	0.0 - 1.2	mg/dL
BILIRUBIN, DIRECT	0.32 High	0.0 - 0.2	mg/dL
METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT METHOD : CALCULATED	0.52	0.00 - 1.00	mg/dL
TOTAL PROTEIN METHOD : BIURET	7.9	6.4 - 8.3	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.6	3.50 - 5.20	g/dL
GLOBULIN METHOD : CALCULATED	3.3	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : UV WITH P5P	16	UPTO 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	21	UPTO 34	U/L
	111 High	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE	19	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : ENZYMATIC LACTATE - PYRUVATE(IFCC)	166	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : UREASE KINETIC	7	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : ALKALINE PICRATE KINETIC JAFFES	0.62	0.50 - 0.90	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD : CALCULATED	11.29	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	6.5 High	2.6 - 6.0	mg/dL



Dr.Arpita Pasari, MD **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel: 0731 2490008



Page 13 Of 21

t

. . View Report View Details

ЪJ;

E

- 39





PATIENT NAME : MRS. KUMARI PUNAM (BOBE	49236)		DR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290	WJ005049	AGE/SEX : 34 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSK	(F050389290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	GLIENT BATIENT ID: (BC	)BE49236)	RECEIVED : 28/10/2023 11:17:58
NEW DELHI 110030			REPORTED :30/10/2023 16:37:00
8800465156			
Test Report Status <u>Final</u>	Results	Biological	Reference Interval Units
METHOD : URICASE/CATALASE UV			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.9	6.4 - 8.3	g/dL
METHOD : BIURET			
ALBUMIN, SERUM			
ALBUMIN	4.6	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN			
GLOBULIN	3.3	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	140.7	136.0 - 14	16.0 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE			
POTASSIUM, SERUM	4.96	3.50 - 5.1	0 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE			
CHLORIDE, SERUM	103.1	98.0 - 106	5.0 mmol/L
METHOD : DIRECT ION SELECTIVE ELECTRODE			

## Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Pepita

Dr.Arpita Pasari, MD Consultant Pathologist

Page 14 Of 21



View Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49236)       REF. DOCTOR : DR. MEDI WHEEL FULL BODY CHECKUP BELOWBELOW 40FE         CODE/NAME & ADDRESS : C000138355       ACCESSION NO : 0290WJ005049       AGE/SEX : 34 Years	MALE emale :17:58
CHECKUP BELOWBELOW 40FE	MALE emale :17:58
CODE/NAME & ADDRESS : C000138355         ACCESSION NO : 0290WJ005049         AGE/SEX : 34 Years         F	:17:58
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	:37:00
Test Report Status         Final         Results         Biological Reference Interval         Unit	ts
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)	
<ul> <li>Interpretation(s)</li> <li>GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION</li> <li>Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is ex urine.</li> <li>Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.</li> <li>Decreased in :Piancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hpopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma).Infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.</li> <li>NOTE: while random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation withit individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.</li> <li>High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of oral Hypoglycaemics &amp; Insulin treatment,Renal Glyosuria,Glycaemics &amp; Sensitivity etc.</li> <li>GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of oral Hypoglycaemics &amp; LIVER FUNCTION PROFILE, SERUM-</li> <li>Bilirubin is a yellowish gingment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoise), decreased bilirubin ex obstruction and hepatitis), and abnormal bilirubin metabolism egt, hereditary and neonatal jaundice. Conjugated (micret) bilirubin to reased more than unconjugated (indirect) bilirubin si also elevated more than unconjugated</li></ul>	a Insulin Insulin HbA1c may give cretion (eg, ugated in when t) bilirubin me that easured nemolytic ne blood.ALT n of

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidi in Hypophosphatasia,Malnutrition,Protein deficiency,Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, bilary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the unitary track, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis



Dr.Arpita Pasari, MD **Consultant Pathologist** 



Page 15 Of 21

Vie<u>w</u> Details View Report





PATIENT NAME : MRS. KUMARI PUNAM (BOBE4			HEEL FULL BOD LOWBELOW 40	
F-703 LADO SARAT MEHRALILISOUTH WEST	PATIENT ID : MRSKF050389290 GLIENT BATIENT ID: (BOBE49236)	DRAWN RECEIVED	:34 Years : :28/10/2023 :30/10/2023	
Test Report Status Final	Results Biological	Reference	e Interval l	Jnits

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. **Lower-than-normal levels may be due to:** Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.



Dr.Arpita Pasari, MD Consultant Pathologist



Page 16 Of 21

View Report







PATIENT NAME : MR	S. KUMARI PUNAM (BOB	E49236) RE	EF. DOCTOR : D		HEEL FULL BO	
CODE/NAME & ADDRESS	5 :C000138355	ACCESSION NO : 0290W	J005049	AGE/SEX	:34 Years	Female
ARCOFEMI HEALTHCARI	•	PATIENT ID : MRSKF0	50389290	DRAWN	:	
F-703, LADO SARAI, M DELHI	EHRAULISOUTH WEST	ABITA NOATIENT ID: (BOBE	49236)	RECEIVED	: 28/10/202	3 11:17:58
NEW DELHI 110030				REPORTED	:30/10/202	3 16:37:00
8800465156						
Test Report Status	Final	Results	Biological	Reference	e Interval	Units
	CLIN	ICAL PATH - URINALYSIS	5			
MEDI WHEEL FULL BO	DDY HEALTH CHECKUP B	ELOW 40FEMALE				
PHYSICAL EXAMINAT	ION, URINE					
COLOR		PALE YELLOW				
APPEARANCE		SLIGHTLY HAZY				
CHEMICAL EXAMINA	FION, URINE					
РН		6.0	4.7 - 7.5			
SPECIFIC GRAVITY		1.010 1.003 - 1.035				
PROTEIN		NOT DETECTED NOT DETECTED				
GLUCOSE		NOT DETECTED	DETECTED NOT DETECTED			
KETONES		NOT DETECTED	NOT DETECTED			
BLOOD		NOT DETECTED	NOT DETE	CTED		
BILIRUBIN		NOT DETECTED	NOT DETE	CTED		
UROBILINOGEN		NORMAL	NORMAL			
NITRITE		NOT DETECTED	NOT DETE	CTED		
LEUKOCYTE ESTERAS	SE	DETECTED (+++)	NOT DETE	CTED		
MICROSCOPIC EXAM	INATION, URINE					
RED BLOOD CELLS		NOT DETECTED	NOT DETE	CTED	/١	HPF
PUS CELL (WBC'S)		30-40	0-5		/١	HPF
EPITHELIAL CELLS		10-15	0-5		/١	HPF
CASTS		NOT DETECTED				
CRYSTALS		NOT DETECTED				
BACTERIA		DETECTED (+)	NOT DETE	CTED		
YEAST		NOT DETECTED	NOT DETE	CTED		

.Please note that all the urinary findings are confirmed manually as well.

## Interpretation(s)

REMARKS

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	

Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 17 Of 21

View Report







## PATIENT NAME : MRS. KUMARI PUNAM (BOBE49236)

### **REF. DOCTOR :** DR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355	ACCESSION NO	D : 0290WJ005049	AGE/SEX	:34 Years	Female
	PATIENT ID	: MRSKF050389290	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ABHAN NOATIEN	T ID: (BOBE49236)	RECEIVED	:28/10/2023	11:17:58
NEW DELHI 110030			REPORTED	:30/10/2023	16:37:00
8800465156					

Test Report Status	<u>Final</u>
--------------------	--------------

Results

Biological Reference Interval Units

Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Bapila

Dr.Arpita Pasari, MD Consultant Pathologist



View Report

View Details

**D**2





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49			IEEL FULL BOD LOWBELOW 40	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0290WJ005049</b> PATIENT ID : MRSKF050389290 CHIENT PATIENT ID: (BOBE49236)	DRAWN RECEIVED	: 34 Years : : 28/10/2023 : 30/10/2023	

Test Rep	ort Status	<u>Final</u>
----------	------------	--------------

Results

**Biological Reference Interval** Units

SPECIALISED CHEMISTRY - HORMONE						
MEDI WHEEL FULL BODY HEALTH CHECK	UP BELOW 40FEMALE					
THYROID PANEL, SERUM						
Τ3	132.80	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	D			
METHOD : CHEMILUMINESCENCE TECHNOLOGY						
T4	11.31	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL			
METHOD : CHEMILUMINESCENCE TECHNOLOGY						
TSH (ULTRASENSITIVE)	3.050	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL			
METHOD : CHEMILUMINESCENCE TECHNOLOGY						

## Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. TSH Total T4 FT4 Total T3	Possible Conditions
-----------------------------------	---------------------

Dr.Arpita Pasari, MD Consultant Pathologist



Patient Ref. No. 775000005251157

Page 19 Of 21



## PATIENT NAME : MRS. KUMARI PUNAM (BOBE49236)

### REF. DOCTOR : DR. MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWBELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290WJ005049	AGE/SEX	:34 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSKF050389290	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST	ABIENT BATIENT ID: (BOBE49236)		: 28/10/2023	11.17.58
		-	:30/10/2023	
NEW DELHI 110030		KLFUKILD	.30/10/2023	10:37:00
8800465156				

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units

1	High	Low	Low	Low	<ul> <li>(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)</li> <li>Post Thyroidectomy (4) Post Radio-Iodine treatment</li> </ul>	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	<ul> <li>(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre</li> <li>(3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy</li> </ul>	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr.Arpita Pasari, MD **Consultant Pathologist**  Page 20 Of 21



View Details





PATIENT NAME : MRS. KUMARI PUNAM (BOBE49		R. MEDI WHEEL FULL BODY HEALTH HECKUP BELOWBELOW 40FEMALE
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0290WJ005049</b> PATIENT ID : MRSKF050389290 GEIENT BATIENT ID: (BOBE49236)	AGE/SEX :34 Years Female DRAWN : RECEIVED :28/10/2023 11:17:58 REPORTED :30/10/2023 16:37:00
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING					
<ol> <li>It is presumed that the test sample belongs to the patient named or identified in the test requisition form.</li> <li>All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.</li> <li>Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.</li> <li>A requested test might not be performed if:         <ol> <li>Specimen received is insufficient or inappropriate ii. Specimen quality is unsatisfactory iii. Incorrect specimen type iv. Discrepancy between identification on specimen container label and test requisition form</li> </ol> </li> </ol>	<ol> <li>AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety &amp; technical integrity.</li> <li>Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.</li> <li>Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.</li> <li>Test results cannot be used for Medico legal purposes.</li> <li>In case of queries please call customer care (91115 91115) within 48 hours of the report.</li> </ol>				
	Agilus Diagnostics Ltd Fortis Hospital, Sector 62, Phase VIII,				

ctor 62, Phase VIII, ortis F Mohali 160062



Dr.Arpita Pasari, MD Consultant Pathologist



Page 21 Of 21



